Scientific Reports · Nov 15, 2026
GLP-1R in JBMMSCs suppressed mandibular injury via modulating PKA/STAT3/TET3/SHP2/β-catenin signaling induced osteoblast differentiation
By Liu H, Bao X, Ge S et al.
To investigate the specific molecular mechanisms of GLP-1R in jaw bone marrow mesenchymal stem cells (JBMMSCs) under the influence of semaglutide on mandibular osteoporosis in rats. Rat osteoporosis samples were chosen for bioinformatics analysis from the GEO database. Additional single‑cell RNA‑seq, pseudotime trajectory, and cell‑cell communication analyses were also performed. Rat mandibles were used to harvest JBMMSCs, which were then identified using flow cytometry. CT was used to measure the degree of osteoporosis in a rat osteoporosis model. The therapeutic benefits of semaglutide-intervened JBMMSCs on osteoporosis and the function of SHP2 in semaglutide’s treatment effectiveness were assessed using H&E staining. JBMMSCs were cultivated in vitro at the optimum semaglutide concentration for osteogenic and adipogenic induction. Osteogenic and adipogenic-related protein expression levels were found using Western blot, and osteogenic and adipogenic differentiation capacities were evaluated by ARS and Oil Red O staining. Additionally, ChIP-qPCR was performed to assess direct transcriptional regulation, and immunofluorescence was used to evaluate β-catenin nuclear translocation. To further investigate the molecular processes by which JBMMSCs ameliorate osteoporosis under semaglutide intervention, the expression levels of GLP-1R, p-PKA, p-STAT3, TET3, t-SHP2, p-SHP2, and β-catenin were evaluated. CT observations revealed that semaglutide-intervened JBMMSCs had a therapeutic effect on osteoporosis, with SHP2 playing a critical role in enhancing semaglutide’s efficacy. Rats treated with semaglutide-intervened JBMMSCs had much less osteoporosis, according to H&E staining. Bioinformatic analysis further revealed that MRONJ‑derived BM‑MSCs exhibited impaired osteogenic potential, enhanced adipogenic predisposition, and dysregulated TGFB1‑driven cell‑cell communication. Semaglutide improves osteoporosis by promoting osteogenesis and inhibiting adipogenesis in JBMMSCs via the PKA/STAT3/TET3/SHP2/β-catenin axis, according to Western blot analysis of associated protein expression levels, which was further corroborated by RT-qPCR at the transcriptional level. Mechanistically, ChIP-qPCR confirmed that p-STAT3 directly binds the TET3 promoter, and TET3 directly binds and demethylates the SHP2 promoter; immunofluorescence further demonstrated that this axis promotes β-catenin nuclear translocation. These results were validated by rescue studies. GLP-1R in JBMMSCs inhibits osteoporosis by regulating osteoblast differentiation induced by the PKA/STAT3/TET3/SHP2/β-catenin signaling pathway.